[PDF] Top 20 Preguntas y Respuestas de Farmacología
Has 5023 "Preguntas y Respuestas de Farmacología" found on our website. Below are the top 20 most common "Preguntas y Respuestas de Farmacología".
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
... Patients’ pre-ERT parameter levels were set as BL and every month regularly assessed with hematological tests, including red blood cell (RBC) count, hemoglobin (Hb), hematocrit (Ht), white blood cell (WBC) count, ... See full document
8
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
... the disease on the mean distance walked and therefore clinically meaningful improvements would not be expected as a result of ...the patients had exercised to their maximum ... See full document
5
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
... change, safety/efficacy of agalsidase alfa were evaluated in enzyme replacement therapy (ERT)-naïve children with Fabry ...mg/kg agalsidase ... See full document
30
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
... either agalsidase alfa or agasidase beta has been developed for FD ...the efficacy and safety of the drug, since FD is very rare. Agalsidase alfa is au- thorized at a dose of ... See full document
34
Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease
... of agalsidase alfa ...Eleven patients were on anticonvulsants (Te- gretol or gabapentin) for neuropathic ...11 patients were able to reduce or stop the use of neuropathic pain medications (P ⫽ ... See full document
8
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
... to patients with classic disease manifestations atyp- ical cases show low plasma lysoGb3 levels ...two alfa-Galactosidase A preparations for treatment of Fabry disease: ... See full document
150
<p>Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis</p>
... of agalsidase alfa ERT, LVMI had relatively small increases among patients with LVH at baseline and was stable among patients without LVH at ...addition, patients without renal ... See full document
6
Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
... of Fabry disease, which manifest as proteinuria and reduced glomerular filtration rate leading to chronic kidney disease and progression to end-stage renal ...of treatment of Fabry ... See full document
14
Update on role of agalsidase alfa in management of Fabry disease
... Abstract: Fabry disease (FD) is an X-linked lysosomal storage disorder that affects both men and ...heterogeneous disease are multisystemic and progres- ...of enzyme replacement ... See full document
11
Role of elosulfase alfa in mucopolysaccharidosis IVA
... storage disease which results in a striking skeletal phenotype, but does not negatively impact the intellect of the ...systemic disease is common and requires aggressive monitoring and ...elosulfase ... See full document
224
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
... untreated Fabry disease differs in some respects in men and women as a result of differences in levels of residual enzyme activity [3, ...of patients being affected by cardiomyopathy, with LVH ... See full document
11
<p>Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age</p>
... untreated patients shown by Arends et al 17 appears to be very different from that shown for cohorts 1 and 2 of this analysis in patients of approximately the same ...untreated patients has been ... See full document
7
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
... Pompe disease. Pompe disease is a rare meta- bolic disease and presents as a broad clinical spectrum, with the rapidly progressive classic-infantile form at the most severe end and late-onset or ... See full document
75
Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
... On multiple linear regression (table 3), age at baseline MRI (p < 0.0005; increasing age associated with faster WMH pro- gression), total cholesterol at baseline MRI (p = 0.03; in- creasing total cholesterol ... See full document
7
Enzyme replacement therapy for Fabry disease: some answers but more questions
... Abstract: Fabry disease (FD) is a multisystem, X-linked disorder of glycosphingolipid metabolism caused by enzyme deficiency of α-galactosidase ...Affected patients have symptoms including ... See full document
9
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
... global enzyme shortage of agalsidase beta and the subsequent dose reductions caused distress and concern in both patients and ...of Fabry disease ...the agalsidase beta shortage ... See full document
102
Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
... Pompe patients has been shown to be more difficult than substrate elimination in other lysosomal storage disorders, and several factors contribute to the limited efficay of enzyme replace- ment ... See full document
14
(INF- ) in combination
... HCV treatment such as hyperimmune anti-HCV immunoglobulins, therapeutic vaccines (monoclonal antibody against a linear epitope of HCV E2 glycoprotein MBL-HCV1 that neutralizes pseudoviruses from multiple HCV ... See full document
14
Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
... adult patients with Pompe ...of treatment and switched to 1 at the start of ...as patients were not receiving ERT, they contributed to the untreated group and acted as controls for the treated ... See full document
56
Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
... combined therapy would not extend to another ...combination therapy, her chitotriosidase levels fell from 4607 to 1339 nmol/h/mL, liver volume remained at ... See full document
35
Related subjects